Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;78(4):446-453.
doi: 10.1136/annrheumdis-2018-213678. Epub 2018 Dec 8.

Genetics of rheumatoid arthritis: 2018 status

Affiliations
Review

Genetics of rheumatoid arthritis: 2018 status

Yukinori Okada et al. Ann Rheum Dis. 2019 Apr.

Abstract

Study of the genetics of rheumatoid arthritis (RA) began about four decades ago with the discovery of HLA-DRB1 Since the beginning of this century, a number of non-HLA risk loci have been identified through genome-wide association studies (GWAS). We now know that over 100 loci are associated with RA risk. Because genetic information implies a clear causal relationship to the disease, research into the pathogenesis of RA should be promoted. However, only 20% of GWAS loci contain coding variants, with the remaining variants occurring in non-coding regions, and therefore, the majority of causal genes and causal variants remain to be identified. The use of epigenetic studies, high-resolution mapping of open chromatin, chromosomal conformation technologies and other approaches could identify many of the missing links between genetic risk variants and causal genetic components, thus expanding our understanding of RA genetics.

Keywords: autoimmune diseases; gene polymorphism; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: KY has received honoraria or research grants from AbbVie, Astellas, AYUMI, Bristol-Myers Squibb, Chugai, Eisai, Janssen, Mitsubishi Tanabe, Ono and UCB. YK has received research grants from Takeda Pharm, Chugai Pharm and Pfizer.

Publication types

MeSH terms

Substances